fbpx Pubblicazioni in evidenza | Istituto di Candiolo - FPO - IRCCS
Lancet Oncology Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis
Cancer Discovery MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer
Nature The genomic landscape of response to EGFR blockade in colorectal cancer
Nat Med. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
Nat Genet. Stromal contribution to the colorectal cancer transcriptome.
Science Tran. Med. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
Lancet Oncol. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Cancer Discov. Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution.
Cancer Res. MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells.
Nature Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

 

Raggiungi l'Istituto di Candiolo

 

  •  Indirizzo per navigatori: Strada Provinciale 142 di Piobesi incrocio Strada Statale 23 del Sestriere  -  Coordinate: 44°58'01.6"N 7°34'00.0"E